Generative biology, which uses AI to design molecules and biological functions, is transitioning from research to clinical application. Companies like Generate Biomedicines and Insilico Medicine are leveraging AI to create therapeutic proteins and small molecule drugs, with several AI-designed medicines now in human trials. This approach promises to accelerate drug discovery, enable the tackling of previously untreatable diseases, and potentially make drug development more programmatic and scalable, though challenges remain in ensuring these AI-generated treatments are effective and safe in humans. AI
IMPACT Accelerates drug discovery and enables new treatments for difficult diseases, though efficacy and safety in humans remain key challenges.
RANK_REASON The article discusses the application of AI in drug discovery and the progress of AI-designed medicines in clinical trials, which represents a significant advancement in research. [lever_c_demoted from research: ic=1 ai=1.0]
- Ai4 2026
- Alex Zhavoronkov
- GB-0895
- Generate Biomedicines
- generative biology
- Gevorg Grigoryan
- Insilico Medicine
- TSLP
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
